Overview

Open-Label Trial of Peripheral Blood Progenitor Cell (PBPC) Mobilization by Filgrastim in Normal Donors

Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to clinically evaluate the spleen during PBPC mobilization by filgrastim in normal donors.
Details
Lead Sponsor:
Amgen
Treatments:
Lenograstim